INmune Bio (NASDAQ:INMB – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday. Separately, Weiss Ratings upgraded INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. One […]

SEI Investments (NASDAQ:SEIC – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday. Several other brokerages also recently commented on SEIC. Raymond James Financial raised their target price on SEI Investments from $122.00 to $124.00 […]

Aktis Oncology (NASDAQ:AKTS – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday. Several other equities analysts have also recently issued reports on AKTS. William Blair began coverage on shares of Aktis Oncology […]

Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday. Other research analysts have also issued reports about the company. Citigroup began coverage on Summit Therapeutics in a research report on Wednesday, […]

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday. Other analysts have also recently issued reports about the company. BTIG Research boosted their price objective on Kestra Medical Technologies from $30.00 to […]

SciSparc (NASDAQ:SPRC – Get Free Report) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report released on Saturday. Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a research report on Tuesday, May 26th. One investment analyst has rated the stock with a Sell […]

Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday. Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One investment analyst has rated the […]

GlucoTrack (NASDAQ:GCTK – Get Free Report) was downgraded by analysts at Wall Street Zen to a “strong sell” rating in a research report issued to clients and investors on Saturday. Separately, Weiss Ratings restated a “sell (e+)” rating on shares of GlucoTrack in a research note on Tuesday, April 21st. One investment analyst has rated […]